Fortune Magazine Names Millennium Among 100 Best Companies to Work For

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Millennium: The Takeda Oncology Company today announced it has been named among the 100 Best Companies to Work For in the United States by FORTUNE. This is the first year that Millennium, a wholly owned subsidiary of Japan’s largest pharmaceutical company Takeda Pharmaceuticals, has been included in this list. Millennium was the highest ranked newcomer on this year’s list.

“Being named among the top 100 employers in the country is a tremendous accomplishment for our company, and a true reflection of the passion, commitment and pride that our employees have for their work,” said Deborah Dunsire, M.D., President and Chief Executive Officer, Millennium. “This recognition from FORTUNE is a result of our Company’s commitment to patients, our community and our own employees.”

Over the past year, Millennium has also been named a top employer by the Boston Globe, the Boston Business Journal, Science magazine, The Scientist and the Dave Thomas Foundation.

Methodology

To pick the 100 Best Companies to Work For, FORTUNE partners with the Great Place to Work Institute to conduct the most extensive employee survey in corporate America. Three hundred eleven companies participated in this year's survey. Two-thirds of a company's score is based on the results of the Institute's Trust Index survey, which is sent to a random sample of employees from each company. The survey asks questions related to their attitudes about management's credibility, job satisfaction, and camaraderie. The other third of the scoring is based on the company's responses to the Institute's Culture Audit, which includes detailed questions about pay and benefit programs and a series of open-ended questions about hiring practices, internal communications, training, recognition programs and diversity efforts. Any company that is at least seven years old with more than 1,000 U.S. employees is eligible.

About Millennium

Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets a first-in-class proteasome inhibitor, and has a robust clinical development pipeline of product candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical Company Ltd. ("Takeda", TSE: 4502) in May, 2008. The Company's research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, www.millennium.com.

Editors’ Note: This press release is also available under the Media section of the Company’s website at: www.millennium.com/media



CONTACT:

Millennium: The Takeda Oncology Company
Manisha Pai, 617-551-7877
[email protected]
or
Lauren Musto, 617-551-7848
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics  Hospitals  Oncology  Pharmaceutical  Other Health  Professional Services  Human Resources  Research  FDA  Science

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.